Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Allogene Therapeutics, Inc. (ALLO) had Return on Equity of -13.27% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-38.81M |
|
-- |
|
-- |
|
$42.40M |
|
$-42.40M |
|
$3.59M |
|
$-38.81M |
|
$-38.81M |
|
$-38.81M |
|
$-38.81M |
|
$-38.81M |
|
$-38.81M |
|
$-42.40M |
|
$-40.17M |
|
220.62M |
|
220.62M |
|
$-0.17 |
|
$-0.17 |
|
| Balance Sheet Financials | |
$257.75M |
|
$72.84M |
|
$158.16M |
|
$415.90M |
|
$32.51M |
|
-- |
|
$90.85M |
|
$123.36M |
|
$292.54M |
|
$292.54M |
|
$292.54M |
|
229.41M |
|
| Cash Flow Statement Financials | |
$-149.25M |
|
$95.56M |
|
$30.16M |
|
$85.51M |
|
$61.98M |
|
$-23.53M |
|
$37.64M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.93 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-149.63M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-13.27% |
-13.27% |
|
-9.33% |
|
-13.27% |
|
$1.28 |
|
$-0.68 |
|
$-0.68 |
|